$267.41
0.12% today
Nasdaq, Feb 28, 04:49 pm CET
ISIN
US45784P1012
Symbol
PODD

Insulet Corporation Stock price

$267.09
-8.81 3.19% 1M
+74.51 38.69% 6M
+6.02 2.31% YTD
+100.47 60.30% 1Y
+2.40 0.91% 3Y
+83.34 45.36% 5Y
+235.36 741.76% 10Y
Nasdaq, Closing price Thu, Feb 27 2025
-3.55 1.31%
ISIN
US45784P1012
Symbol
PODD
Sector

Key metrics

Market capitalization $18.76b
Enterprise Value $19.23b
P/E (TTM) P/E ratio 46.14
EV/FCF (TTM) EV/FCF 62.95
EV/Sales (TTM) EV/Sales 9.28
P/S ratio (TTM) P/S ratio 9.05
P/B ratio (TTM) P/B ratio 15.47
Revenue growth (TTM) Revenue growth 22.07%
Revenue (TTM) Revenue $2.07b
EBIT (operating result TTM) EBIT $308.90m
Free Cash Flow (TTM) Free Cash Flow $305.40m
Cash position $953.40m
EPS (TTM) EPS $5.79
P/E forward 62.68
P/S forward 7.65
EV/Sales forward 7.85
Short interest 4.11%
Show more

Is Insulet Corporation a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,809 stocks worldwide.

Insulet Corporation Stock Analysis

Unlock Scores for Free

Analyst Opinions

24 Analysts have issued a Insulet Corporation forecast:

20x Buy
83%
4x Hold
17%

Analyst Opinions

24 Analysts have issued a Insulet Corporation forecast:

Buy
83%
Hold
17%

Financial data from Insulet Corporation

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
2,072 2,072
22% 22%
100%
- Direct Costs 612 612
14% 14%
30%
1,460 1,460
26% 26%
70%
- Selling and Administrative Expenses 846 846
28% 28%
41%
- Research and Development Expense 220 220
7% 7%
11%
394 394
35% 35%
19%
- Depreciation and Amortization 85 85
17% 17%
4%
EBIT (Operating Income) EBIT 309 309
40% 40%
15%
Net Profit 418 418
103% 103%
20%

In millions USD.

Don't miss a Thing! We will send you all news about Insulet Corporation directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Insulet Corporation Stock News

Positive
FXEmpire
2 days ago
Insulet Corporation (PODD) continues its strong sales and growth trend.
Neutral
Seeking Alpha
8 days ago
Insulet Corporation (NASDAQ:PODD ) Q4 2024 Earnings Conference Call February 20, 2025 4:30 PM ET Company Participants June Lazaroff - Senior Director of Investor Relations Jim Hollingshead - President & Chief Executive Officer Ana Chadwick - Executive Vice President, Chief Financial Officer & Treasurer Conference Call Participants Robert Marcus - JPMorgan Jeffrey Johnson - Baird Travis Steed - ...
Positive
Reuters
8 days ago
Insulet reported a higher-than-expected profit in the fourth quarter on Thursday, driven by strong demand for its wearable insulin pumps.
More Insulet Corporation News

Company Profile

Insulet Corp. is a medical device company. The firm engages in the development, manufacture and marketing of an insulin infusion system for people with insulin-dependent diabetes. It specializes in diabetes supplies, including the OmniPod System as well as other diabetes related products and supplies such as blood glucose testing supplies, traditional insulin pumps, pump supplies, and pharmaceuticals. The company was founded by John L. Brooks III and John T. Garibotto in July 2000 and is headquartered in Acton, MA.

Head office United States
CEO James Hollingshead
Employees 3,900
Founded 2000
Website www.insulet.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today